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Abstract: HCV infection is a serious concern among people who inject drugs. Despite imposing a major disease burden
in countries with high rates of injection drug use such as Kazakhstan, other Central Asian and East Asian countries,
Eastern Europe, and Russia, HCV remains an understudied issue. This study includes 728 individuals (364 couples)
from Almaty, Kazakhstan, where at least one member of the dyad reported recent injection drug use. Participants were
recruited to participate in a couple-based HIV prevention study. We examine the prevalence of HCV and co-infections
between HCV and HIV, correlates of HCV, and the association between HCV prevalence and sexual behaviors after
adjusting for non-injection illicit drug use, unsafe injection behaviors, and socio-demographic characteristics. Of the total
sample, 90.2% of people who had ever injected drugs were diagnosed HCV positive and 15.5% of those who did not
report injecting drugs were HCV positive. The prevalence of HIV and HCV co-infection among the total sample was
20.7%. In the multivariate analysis, having sex while high on alcohol and/or drugs was associated with HCV after
adjusting for unsafe injection practices, non-injection drug use, and socio-demographic characteristics (PR=1.20; 95%
CI=1.04, 1.39). The high rates of HCV and co-infection of HIV and HCV found in the study underscore the need for
attention to HCV testing and treatment among people who inject drugs in Kazakhstan and their sex partners.

Keywords: HCV, Injection drug use, Central Asia, HIV, Kazakhstan.
INTRODUCTION
A recent review estimating global, national, and
regional prevalence rates of HCV among injection drug
users (IDUs) in 77 countries found that HCV rates
among IDUs ranged from 60-80% [1]. The review
estimated that approximately 10 million IDUs (6.0-15.2
million) worldwide had been exposed to HCV; thus,
more IDUs are living with HCV than HIV(1). HCV
imposes a major disease burden in countries that have
high rates of IDU, such as Kazakhstan, other Central
Asian and East Asian countries, Eastern Europe, and
Russia [2-7]. UNAIDS estimates that 1% of
Kazakhstani adults inject drugs [8]; however, this
proportion exceeds 10% in towns along major drug
trafficking routes across the country, representing one
of the highest rates of injection drug use in the world
[8].
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HCV is transmitted through unsafe injection
practices [1, 3] including sharing needles and other
injection equipment such as cookers, rinse water,
filters, or cotton [9]. Most people who become infected
with HCV (75-85%) develop chronic HCV infection,
which can result in liver damage and liver failure over
time [10]. Non-injection drug use has also been found
to be associated with HCV infection. Drug users who
do not inject can spread HCV by sharing straws/spoons
to snort heroin or cocaine [2-4, 11-14] or by sharing
crack smoking paraphernalia between people with oral
lesions [15, 16], but studies on the link between HCV
infection and non-injection drug use remain limited.
Other factors found to be associated with HCV infection
include older age [9, 17], a history of incarceration or
detention, unsafe medical injections or transfusions [1],
drug treatment [18], and duration of injection use,
especially when longer than 10 years of use [9, 19].
HCV may also be spread through sexual contact,
although transmission is less efficient than other
sexually transmitted infections (STIs) [20-22]. Several
case-controlled studies conducted mainly in the U.S.
have identified well-documented instances of HCV
© 2014 Synergy Publishers
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infection after a defined sexual exposure [22-27].
Among patients with acute HCV infection in the U.S.,
15-20% with no history of drug use reported a history of
sexual contact with a person infected with HCV [22].
HCV infection has also been found to be associated
with sexual risk behaviors among IDUs, including
unprotected sex with someone who is HIV positive [3],
anal sex, failure to use condoms, as well as having a
higher number of sexual partners, a history of STIs, a
sex partner with HCV infection [11, 28], and engaging
in sex work [29]. In a study among heterosexual
couples in an STI clinic in the U.S., females with HCV
were 3.7 times more likely than those without HCV to
have a HCV positive partner [30]. In spite of this
growing evidence linking sexual risk behaviors and
HCV infection, the mechanisms of sexual acquisition
and transmission have not yet been identified.
To understand the spread of HCV, it is crucial to
consider multiple structural factors that have been
found to contribute to HIV risk among IDUs, including a
lack of access to sterile needles, fear of harassment,
discrimination, [31-34] poverty, arrest and incarceration
[35-37], and barriers to HIV services and drug
treatment [38-40]. These risk environments may also
contribute to HCV among people who inject drugs.
As in other Central Asian countries, people who
inject drugs face a number of governmental policies
and structural barriers that prevent them from
accessing harm reduction services and HCV and HIV
care. While access to syringes and needles is legal and
Kazakhstan currently has over 150 syringe/needle
exchange programs, only 10-14% of IDUs utilize them
[8]. The majority of people who inject drugs receive
their syringes/needles from pharmacies. Methadone
maintenance treatment was initiated in Kazakhstan in
October 2008 as a pilot intervention for HIV positive
IDUs within the national multicomponent HIV treatment
project funded by the Global Fund to Fight AIDS,
Tuberculosis, and Malaria (GFATM). Recently, three
new pilot sites (Pavlodar, Temirtau, and UstKamenogorsk) were added, but political opposition has
limited progress [41].
This paper describes the prevalence of HCV and
co-infections of HCV and HIV among a sample of 728
individuals recruited to an HIV couple-based
intervention.
We describe the prevalence of HCV by: (1) sociodemographic and economic characteristics (age,
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marital status, ethnicity, homelessness, food insecurity,
and incarceration history); (2) injection drug use; (3)
non-injection drug use; and (4) sexual risks. We
describe associations between HCV and unsafe sexual
practices (Having syphilis, engaging in unprotected
sex, having more than one sex partner, using alcohol
or drugs before sex), controlling for the effect of unsafe
injection and socio-demographic characteristics, to
explore if sexual risks (syphilis, unprotected sex,
having multiple partners, using alcohol or drugs prior to
sex) are associated with HCV. Although participants
were recruited using a convenience sample, this
descriptive study provides important data on a topic
that has not been addressed in Kazakhstan and
Central Asia.
METHODS
Data Source
This study uses baseline data from NIDA-funded
Project Renaissance, conducted between 2009 and
2012 in Almaty, Kazakhstan. Project Renaissance was
a randomized controlled trial to test the efficacy of a
dyadic-focused HIV prevention intervention for couples
where one or both partners report injecting drugs within
90 days. The Columbia University Institutional Review
Board and the Kazakhstan School of Public Health
Institutional Review Board approved the study.
Recruitment Strategies
Trained research assistants recruited potential
study participants from known neighborhoods where
IDUs gather as well as HIV clinics and needle
exchange programs. Participants were also recruited
via word-of-mouth from participants to their injection
network members.
Eligibility Criteria
Inclusion Criteria
Couples were eligible to participate if they met the
following criteria: (1) both were aged 18 or older; (2)
both identified each other as their main partner of the
opposite sex and someone whom the participant
considered a boy/girlfriend, spouse, lover and/or parent
of his/her child; (3) both reported the relationship had
existed for at least 3 months; (4) both reported
intending to remain together for at least 12 months; (5)
at least one partner reported having had unprotected
vaginal or anal intercourse with the other partner within
the previous 90 days; and (6) at least one partner
reported injecting drugs within the previous 90 days.

HCV among Male Injection Drug Users and their Female Partners in Almaty

Exclusion Criteria
Couples were excluded if they met any of the
following criteria: (1) either partner showed evidence of
psychiatric, physical, or neurological impairment that
would limit effective participation in the study; (2) either
partner reported severe physical or sexual violence
perpetrated by the other partner in the past year, as
determined on a Revised Conflict Tactics Scale [42];
(3) either partner reported that the couple was planning
a pregnancy within the next 18 months; or (4) either
partner was not fluent in Russian as determined during
the informed consent process. Couples trying to get
pregnant were excluded as the intervention was
designed to increase condom use and couples trying to
become pregnant may not be using condoms. A total of
971 individuals completed the screening interview. Of
these, 728 met study eligibility criteria and completed
the baseline interview. Of the 971 screened, 33 people
were eligible but did not return to participate in the
baseline.
Data Collection
Data collection included both self-reported data and
objective biological assays. During the baseline visit,
participants completed a 1.5-hour Audio Computer
Assisted Self-Interview (ACASI) conducted in Russian
in a private room. After the interview was completed, a
Clinical Research Coordinator (CRC) conducted
individual pre-test counseling related to HIV, HCV, and
syphilis with each participant in a private room. Within
two weeks of the baseline interview, the CRC notified
each participant privately of his or her HIV, HCV, and
syphilis test results, conducted post-test counseling,
and provided referrals and navigation to treatment
when applicable. Participants received the equivalent
of $10 USD for completing the baseline ACASI
interview and biological testing.
Measures
Socio-Demographic Variables
Self-reported information was collected about
participant socio-demographic characteristics including
gender, age, ethnicity (Kazakh, Russian, or “other”),
marital status (legally married and common-law
marriage as “married,” or divorced, separated,
widowed, or never married as “unmarried”), and
children (have children under 18 or not). Socioeconomic variables included years of education,
homelessness (having no place to sleep within 90
days), and food insecurity (having insufficient money
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for food within 90 days). Measures of legal history
included a history of incarceration.
Current and Past Drug Use
The Risk Behavior Assessment (RBA) [43, 44] was
used to assess HCV risk behaviors and past drug use
historically and within 90 days. Participants were
considered to be injection drug users if they reported
ever injecting drugs. Unsafe injection behaviors
included using unclean syringes/needles; sharing
cookers, cotton, rinse water, and other paraphernalia;
splitting drug solutions with other injectors through
front-loading, back-loading, or use of the same
cooker/spoon, or adding their own or someone else’s
blood into an injected drug. If participants reported
engaging in one or more of these behaviors within 90
days, their response was coded as 1=Yes for “any
unsafe injection act within 90 days.”
We also assessed the number of people a
participant injected with within 90 days. We examined
whether or not other drugs, including Demerol,
morphine,
Benadryl
(diphenhydramine),
speed,
ephedrine, methadone, and Seduxen were mixed with
heroin when a participant reported injecting heroin
within 90 days. Participants reported whether they had
used the following non-injection drugs within 90 days:
heroin (smoked), marijuana (smoked), non-prescribed
sedatives or barbiturates (Dimedrol, Seconal, Luminal,
Librium, etc.), tranquilizers, sleeping pills or
benzodiazepines (Valium, Relanium, Seduxen, etc.),
methamphetamines (Fenamin, speed, Vint), or
cocaine. Non-injection illicit drug use included whether
the participant had used any non-injection drugs within
90 days. We assessed binge drinking by asking
whether or not participants reported consuming 5 or
more alcoholic drinks in a 6-hour period within 90 days.
Sexual Behaviors
Data were collected on sexual behaviors within 90
days including having unprotected vaginal sex with any
partner, having vaginal sex with multiple partners, and
having had vaginal or anal sex under the influence of
alcohol or drugs with the main study partner.
Biological Testing
Biological assays were used to detect HIV, HCV,
and syphilis. For HIV, HCV, and syphilis testing, a dried
blood spot (DBS) technique was applied. A whole
blood spot was obtained by a finger prick, applied to
five printed circles on DBS filter paper cards, and sent
to the reference laboratory at the Republican AIDS
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Center (RAC). For the serologic surveillance of HIV,
HCV, and syphilis, a standard enzyme-linked
immunosorbent assay (ELISA test manufactured by
Abbott Murex) was used [45]. Tests for all three
biomarkers were conducted using a serial two-test
strategy, as recommended by the World Health
Organization and routinely used at the RAC. U.S.
manufactured Abbott Murex Biotech tests were used
for the second test. According to the RAC Guidelines
for Serological Surveillance, the Murex anti HIV
ABBOTT, Murex anti HCV ABBOTT, and the ICE
Syphilis Murex ABBOTT each have a reported
sensitivity of >99.9% and specificity of 99%.
Statistical Analysis
We used Chi-square tests or t-tests to test the
bivariate relationships between HCV infection and each
of the socio-demographic characteristics, injection drug
use, non-injection drug use, and sexual risk behaviors.
We examined whether sexual risks (syphilis antibody
test positive, unprotected vaginal sex, having multiple
sex partners, using alcohol or drugs before sex) were
associated with HCV after adjusting for unsafe
injection, non-injection drug use, and socio demographics (age, gender, marital status, years of
education, and ethnicity).
To examine these associations, we performed a
multivariate modified Poisson regression with random
effects, which accommodated within-couple correlation
due to non-independency of couple data.
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The Poisson regression model was modified with a
robust error variance (“Sandwich” or empirical
covariance matrix) to yield a more reliable estimation of
the confidence interval. The model also included
covariance
adjustment
for
socio-demographic
characteristics. Prevalence ratios (PR) and their
associated 95% confidence intervals (CI) are reported.
All statistical analyses were performed in SAS 9.2.
RESULTS
Socio-Demographic Characteristics
Table 1 reports socio-demographic characteristics
of 728 participants. The average age was 35.8 years
(SD=7.8) and the majority of the sample was of
Russian ethnicity (65.7%). Nearly half (48.8%) reported
experiencing food insecurity within 90 days. Over twothirds of participants (67.0%) had a history of
incarceration. Participants had completed 11.4 years of
education, on average.
HCV positive participants tended to be slightly older
than those who were HCV negative (36.4 years vs.
33.7 years; p<0.01). A greater number of HCV positive
participants reported experiencing food insecurity
within 90 days, compared to HCV negative participants
(51.1% vs. 41.8%; p<0.05). Incarceration rates were
also higher among participants who were HCV positive
when compared to those who were HCV negative
(80.4% vs. 26.9%; p<0.01).

a

Table 1: Socio-Demographic Characteristics by HCV Status (N=728, Female=364, Male=364)
Total

HCV+

HCV-

35.8 (7.8)

36.4 (7.3)**

33.7 (8.9)

Married/common law marriage

629 (86.4)

475 (87.0)

154 (84.6)

Unmarried

99 (13.6)

71 (13.0)

28 (15.4)

11.4 (3.3)

11.4 (3.4)

11.5 (3.0)

Kazakh

85 (11.7)

63 (11.5)

22 (12.1)

Russian

478 (65.7)

365 (66.9)

113 (62.1)

Other

165 (22.7)

118 (21.6)

47 (25.8)

Has children < 18, n (%)

385 (52.9)

281 (51.5)

104 (57.1)

Homeless within 90 days, n (%)

98 (13.5)

78 (14.3)

20 (11.0)

Insufficient money to buy food within 90 days, n (%)

355 (48.8)

279 (51.1)*

76 (41.8)

Ever incarcerated, n (%)

488 (67.0)

439 (80.4)**

49 (26.9)

Age in years, mean (SD)
Marital status, n (%)

Years of education, mean (SD)
Ethnicity, n (%)

*p<0.05; **p<0.01.
Note: a. The significance tests for difference between HCV status were performed by chi-square or t-tests.
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HCV Prevalence
Table 2 shows that the prevalence of HCV for the
total sample was 75.0%. Male participants had a
significantly higher HCV prevalence than females
(88.2% vs. 61.8%; p<0.01), but men also had higher
prevalence of ever injecting drugs (96.4%) when
compared to women (62.9%). Among those who
reported a history of injection drug use, HCV
prevalence was not significantly different by gender.
Some female participants who reported never injecting
drugs had been infected with HCV (14.8%). In 48.4% of
HCV infections identified, the individual was not
previously aware of being HCV positive.
More than half of the couples in the study (56.0%)
were HCV seroconcordant, over a third (37.9%) were
HCV serodiscordant, and in 6.0% of the couples, both
partners were HCV negative. Among the total sample,
the rate of HIV and HCV co-infection was 20.7%. The
co-infection rate was higher among IDUs than nonIDUs (25.5% vs. 2.0%; p<0.01).

Journal of Therapy and Management in HIV Infection, 2014, Vol. 2, No. 1

5

injection drug use (n=580). The mean duration of
injection history among IDUs was 15.6 years (SD=7.8
years), with HCV positive participants reporting a
longer history of injection than HCV negative
participants (16.1 years vs. 10.6 years; p<0.01). A
number of injecting risk behaviors were associated with
HCV positive status (see Table 3).
HCV positive participants were more likely than
HCV negative participants to report use of non-injection
drugs and binge drinking within 90 days.
HCV Prevalence and Sexual Risk
Table 3 describes the prevalence of HCV by sexual
risk behaviors. One-fifth of those who had multiple
sexual partners within 90 days were HCV positive while
HCV negative participants were less likely to have
multiple partners (21.1% vs. 13.2%; p<0.05). HCV
positive participants were also more likely to report
drinking alcohol or taking drugs before vaginal sex
within 90 days than HCV negative participants (85.4%
vs. 57.1%; p<0.01).

HCV Prevalence and Drug Risks
Table 3 describes HCV prevalence and injection
drug risk behaviors among participants with a history of

Table 2: HCV Characteristics

Table 4 reports the multivariate regression model
examining HCV prevalence and sexual risk when
adjusting for unsafe injection, non-injection drug use,

a

Total (N=728)

Female (n=364)

Male (n=364)

546 (75.0)

225 (61.8)

321 (88.2)**

523 (90.2)

205 (89.5)

318 (90.6)

23 (15.5)

20 (14.8)

3 (23.1)

New detections of HCV, n (%) (among total HCV positive,
n=546)

264 (48.4)

117 (52.0)

147 (45.8)

HIV positive, n (%)

183 (25.1)

80 (22.0)

103 (28.3)*

Total (N=728)

IDUs (N=580)

Non-IDUs (N=148)

HCV positive, n (%)
HCV positive among IDUs (n=580)
HCV positive among non-IDUs (n=148)

Co-occurring HIV/HCV

Both HIV and HCV positive, n (%)

151 (20.7)

148 (25.5)**

3 (2.0)

HIV positive and HCV negative, n (%)

32 (4.4)

19 (3.3)

13 (8.8)**

HIV negative and HCV positive, n (%)

395 (54.3)

375 (64.7)**

20 (13.5)

Couple-level status of HCV (N=364)
Concordant positive, n (%)

204 (56.0)

Serodiscordant, n (%)

138 (37.9)

Male positive and female negative

117 (32.1)

Male negative and female positive

21 (5.8)

Concordant negative, n (%)
*p<0.05; **p<0.01.
Note: a. The significance tests for gender and IDU status difference were performed by chi-square tests.

22 (6.0)
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Table 3: Sexual Risk, Injection and Non-Injection Drug Use by HCV Status (N=728)
Total

HCV+

HCV-

92 (12.6)

70 (12.8)

22 (12.1)

Had unprotected vaginal sex with any partner within 90 days,
n (%)

638 (87.6)

485 (88.8)

153 (84.1)

Had more than one sexual partner within 90 days, n (%)

139 (19.1)

115 (21.1)*

24 (13.2)

Drank alcohol or took drugs before vaginal or anal sex with
main partner within 90 days, n (%)

570 (78.3)

466 (85.4)**

104 (57.1)

15.6 (7.8)

16.1 (7.7)**

10.6 (6.6)

510 (87.9)

465 (88.9)*

45 (79.0)

411 (70.9)

379 (72.5)**

32 (56.1)

163 (28.1)

153 (29.3)

10 (17.5)

187 (32.2)

176 (33.7)*

11 (19.3)

38 (5.2)

35 (6.4)*

3 (1.7)

Smoked heroin within 90 days

49 (6.7)

34 (6.2)

15 (8.2)

Used cocaine within 90 days

14 (1.9)

10 (1.8)

4 (2.2)

Sexual risk behaviors (n=728), n (%)
Syphilis antibody test positive, n (%)

Injection drug use (n=580), n (%)
b

Duration of drug injection history in years, mean (SD)
b

Injected drugs within 90 days, n (%)
b

Unsafe injections within 90 days, n (%)
b

Had more than one injecting partner within 90 days, n (%)
b

Mixed with Benadryl when injecting heroin within 90 days, n
(%)
Had access to needle exchange program within 90 days, n
(%)
Non-injection drug and alcohol use (n=728), n (%)

Used methamphetamines within 90 days

13 (1.8)

10 (1.8)

3 (1.7)

Used marijuana within 90 days

368 (50.5)

323 (59.2)**

45 (24.7)

Used non-prescribed sedatives, barbiturates, tranquilizers,
sleeping pills or painkillers within 90 days

423 (58.1)

386 (70.7)**

37 (20.3)

Illicit non-injection drug use within 90 days

527 (72.4)

459 (84.1)**

68 (37.4)

Binge drinking within 90 days

505 (69.4)

387 (70.9)

118 (64.8)

Proportion of # of days binge drinking within 90 days (mean,
SD), n (%)

0.11 (0.20)

0.12 (0.21)*

0.09, 0.16

*p<0.05; **p<0.01.
Note: a. The significance tests for difference between HCV status were performed by chi-square tests. b. The analysis for drug-related risk behaviors only included
those who had ever injected drugs (N=580). Data are missing for 20 IDU cases (16 HCV positive, 4 HCV negative).
a

Table 4: Multivariate Modified Poisson Regression of HCV Status and Risk Behaviors with Random Effects
PR

95% CI

P-value

Unsafe injections within 90 days

1.38

[1.25, 1.53]

<0.01**

Illicit non-injection drug use within 90 days

1.56

[1.32, 1.83]

<0.01**

Syphilis antibody test positive

1.09

[0.97, 1.21]

0.139

Had unprotected vaginal sex with any partner within 90 days

0.96

[0.84, 1.11]

0.583

More than one sexual partner within 90 days

1.00

[0.92, 1.08]

0.942

Drank alcohol or took drugs before vaginal or anal sex with study
partner within 90 days

1.20

[1.04, 1.39]

0.014*

*p<0.05; **p<0.01.
Note: a. The adjusted covariance are gender, age, marital status, years of education, and ethnicity.

and socio-demographic covariance. Using alcohol or
drugs before sex with the study partner within 90 days

was associated with HCV in the multivariate analysis
(PR=1.20; 95% CI=1.04, 1.39).
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DISCUSSION
The 90% prevalence of HCV among IDUs supports
earlier studies on the nexus between injection drug use
and HCV [1, 17]. A significant number of people who
had injected drugs in this study were unaware that they
were HCV positive – almost half of the HCV positive
cases were newly detected.
A key finding from this study is that more than 14%
of the female partners who reported no history of IDU
were HCV positive. Some of these women may have
injected drugs, but did not disclose use. These women
may also have acquired HCV through risky sex with an
HCV infected male partner, as one-third of the couples
in the study were in HCV serodiscordant relationships
in which the male partner was HCV positive.
Food insecurity may serve as a proxy for extreme
poverty among study participants. Participants who did
not have sufficient money to buy food had a higher
prevalence of HCV than their counterparts. The rate of
incarceration was higher among participants who were
HCV positive compared to those who were negative.
Being incarcerated may increase the risk of HCV. In
prisons in Kazakhstan there is no access to clean
needles and harm reduction services, which may
increase risks for acquiring HCV.
The finding that those who mixed heroin with
diphenhydramine (Benadryl) had a higher prevalence
of HCV than their counterparts could indicate that this
mixture is a marker of addiction severity and higher
frequency of injection. Benadryl may be used with
lower quality heroin, to reduce side effects or allergic
reactions, suggesting an association with drug users
who are more economically vulnerable. Alternatively,
mixing heroin with Benadryl can involve injecting the
contents of capsules, which can cause obstructed
veins, infections, or deep vein thrombosis [46], or using
chopped pills which requires larger syringes and
needles that may increase transmission likelihood.
Those who had ever attended a needle exchange
program, compared to those who had not, also had a
higher prevalence of HCV. Those who attended needle
exchange programs may be more severely addicted, in
worse physical condition, or older than IDUs who did
not access needle exchange programs. People who
use drugs in Kazakhstan are less likely to obtain
needles from a needle exchange programs than from a
pharmacist because of police harassment and limited
hours of operation at needle exchange programs.
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Excessive policing and fear of arrest can lead to
sharing drug equipment, thus increasing risks of HCV,
especially in public places where people who use drugs
may rush injections. Individuals who cannot afford
sufficient food may also be unable to purchase
needles/syringes from pharmacists.
The prevalence of HCV among participants who
reported using non-injection drugs such as marijuana,
hashish, barbiturates, and/or binge drinking was higher
than those who did not use these non-injection drugs or
alcohol. The link between non injection drug use and
HCV has been explained by previous research showing
that drug use practices such as sharing pipes, spoons,
or straws to sniff or snort drugs may increase HCV risk
among non-IDUs [3, 5, 11, 13, 14, 19]. However, the
mechanisms that explain the relationship between use
of non-injection drugs and HCV need further
investigation. Non-injection drug use among IDUs may
be a marker of severity or duration of addiction, which
increases the propensity to engage in high-risk drug
behaviors that may lead to acquiring HCV [3, 9].
In the multivariate analysis examining the
relationship between HCV and sexual risk, only using
drugs or alcohol before having sex was associated with
HCV infection. Those who use drugs and alcohol prior
to sex may be less likely to use condoms during sex,
which may increase risks for acquiring HCV. This link,
however, needs further investigation. Research on
sexual risk behavior and HCV remains limited,
especially regarding the mechanisms that link the two
among people who inject drugs.
Because this study was conducted with a nonrandom sample, findings may not be generalized to all
people who inject drugs in Kazakhstan. Moreover,
because of the cross-sectional nature of the study, the
temporal relationships between risk behaviors and
HCV infection cannot be determined. The descriptive
findings reported in this paper provide insight on the
scope of HCV prevalence and correlates with HCV
among a sample that participated in an HIV prevention
study. The study does not examine important
environmental risk factors that may drive HCV such as
fears of harassment and discrimination. Despite these
limitations, the findings provide insight on the scope of
HCV among people who use drugs in Kazakhstan. The
findings also demonstrate major correlates with HCV,
providing important HCV prevention, testing, and
treatment implications that may also affect the HIV
epidemic.
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